focus -WSS

focus

author：knowledge 2025-09-28 00:51:30 - browse：25676

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Test for long Covid? Researchers find new clue in blood samples

hotspot

WSS

Pharmacists can make shortage drugs, but at what cost?

Copay coupons to count toward deductibles, after Biden court move

Will Ozempic

STAT Readout Newsletter: Today's biggest biotech updates

Biotech venture capitalists face new demands from investors

Hospital price transparency does save money, advocate argues

hotspot

focus

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth’s board chair also owns a personal investment firm

Medicare proposal to cover medical devices draws a mixed reaction

Copay coupons to count toward deductibles, after Biden court move

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Studies point to risks of excluding people with obesity from drug trials

After affirmative action ruling, medical educators look to 'holistic review'

CEOs share strategies for surviving biotech slump

Anesthesiologist group: stop taking Ozempic before surgery

STAT Summit: How a Chicago ER doctor tackles gun violence

hotspot

Solve the antibiotic resistance crisis with preventive drugs

Biotech venture capitalists face new demands from investors

EU regulator recommends expanding Mounjaro approval to obesity

Eli Lilly expects to double planned employment in Boston center

Pharmacists can make shortage drugs, but at what cost?

NIH confirmation hearing shows politicization of research

entertainment

hotspot

hotspot

focus